



CORRIGENDUM

Galangin Improved Non-Alcoholic Fatty Liver Disease in Mice by Promoting Autophagy [Corrigendum]

Zhang X, Deng Y, Xiang J, et al. *Drug Des Devel Ther.* 2020;14:3393–3405.

Provincial Health Committee's General Subsidy Project (20200100), General Program of National Natural Science Foundation of China (8187032317) and In-hospital Youth Fund of Xiangya Hospital of Central South University (2015Q03).

The authors have advised that the Acknowledgments statement before the Disclosure section was missed on page 3404 of the published paper. The Acknowledgments statement should read as follows:

Acknowledgments

This work was supported by Youth Program of National Natural Science Foundation of China (21708050), Hunan

Drug Design, Development and Therapy downloaded from <https://www.dovepress.com/>
For personal use only.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also

been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

